Outcomes and predictors of readmission after implantation of a percutaneous left atrial appendage occlusion device in the United States: A propensity score-matched analysis from The National Readmission Database.

AF-atrial fibrillation ECI-Elixhauser comorbidity index ICD-10-International Classification of Diseases-tenth revision LAAO-left atrial appendage occlusion NRD-National Readmission Database

Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
11 2021
Historique:
revised: 26 08 2021
received: 24 06 2021
accepted: 08 09 2021
pubmed: 19 9 2021
medline: 1 12 2021
entrez: 18 9 2021
Statut: ppublish

Résumé

Left atrial appendage occlusion (LAAO) devices have become a favorable alternative option among nonvalvular atrial fibrillation (AF) patients with long-term contraindication to anticoagulation. Real-world experience with postprocedural readmission rates and predictors of readmission in LAAO patients is limited. To assess all-cause 30-day readmission rate and predictors of readmission after LAAO procedure in the United States. This retrospective observational study included all AF patients undergoing percutaneous LAAO procedures in the United States from January 1, 2016, and December 31, 2017, in the National Readmission Database. The primary outcome measure was all-cause 30-day readmission. A propensity score-matched analysis compared outcomes with a non-LAAO AF cohort. Among 14 024 LAAO procedures (age: 76 ± 8 years; 60.5% males), 9.4% were readmitted within 30-days and, 0.2% died during their index hospitalization. The most frequent primary diagnosis during readmission among LAAO was gastrointestinal bleeding (12%). The incidence of LAAO procedures increased by 102%. In the multivariate model, gender and CHA The readmission rate following the LAAO procedure is substantial (approximately 10%), and largely attributable to gastrointestinal bleeding. Factors such as drug abuse and anemia must be explored further to minimize readmission risk.

Sections du résumé

BACKGROUND
Left atrial appendage occlusion (LAAO) devices have become a favorable alternative option among nonvalvular atrial fibrillation (AF) patients with long-term contraindication to anticoagulation. Real-world experience with postprocedural readmission rates and predictors of readmission in LAAO patients is limited.
OBJECTIVE
To assess all-cause 30-day readmission rate and predictors of readmission after LAAO procedure in the United States.
METHOD
This retrospective observational study included all AF patients undergoing percutaneous LAAO procedures in the United States from January 1, 2016, and December 31, 2017, in the National Readmission Database. The primary outcome measure was all-cause 30-day readmission. A propensity score-matched analysis compared outcomes with a non-LAAO AF cohort.
RESULT
Among 14 024 LAAO procedures (age: 76 ± 8 years; 60.5% males), 9.4% were readmitted within 30-days and, 0.2% died during their index hospitalization. The most frequent primary diagnosis during readmission among LAAO was gastrointestinal bleeding (12%). The incidence of LAAO procedures increased by 102%. In the multivariate model, gender and CHA
CONCLUSION
The readmission rate following the LAAO procedure is substantial (approximately 10%), and largely attributable to gastrointestinal bleeding. Factors such as drug abuse and anemia must be explored further to minimize readmission risk.

Identifiants

pubmed: 34535939
doi: 10.1111/jce.15247
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2961-2970

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;(1402):e125-e151.
Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125.
Centers for Disease Control and Prevention. Atrial fibrillation. Accessed August 29, 2020. https://www.cdc.gov/heartdisease/atrial_fibrillation.htm#:%7E:text=It%20is%20estimated%20that%20betweennie
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
Holmes DR, Jr., Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64(1):1-12.
Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70(24):2964-2975.
Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312(19):1988-1998.
Freeman JV, Varosy P, Price MJ, et al. The NCDR left atrial appendage occlusion registry. J Am Coll Cardiol. 2020;75(13):1503-1518.
Kabra R, Girotra S, Vaughan Sarrazin M. Clinical outcomes of mortality, readmissions, and ischemic stroke among medicare patients undergoing left atrial appendage closure via implanted device. JAMA network open. 2019;2(10):e1914268.
Healthcare Cost and Utilization Project. National readmission database. Accessed August 29, 2020. https://wwwhcup-usahrqgov/db/nation/nrd/Introduction_NRD_2010-2017jsp
von Elm E, Altman DG, Egger M, et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573-577.
Pasupula DK, Bhat A, Siddappa Malleshappa SK, et al. Impact of change in 2010 American Heart Association Cardiopulmonary Resuscitation Guidelines on survival after out-of-hospital cardiac arrest in the United States: an analysis from 2006 to 2015. Circ Arrhythm Electrophysiol. 2020;13(2):e007843.
Pasupula DK, Bhat AG, Siddappa Malleshappa SK, et al. Trends and predictors of 30-day readmission among patients hospitalized with infective endocarditis in the United States. Cureus. 2019;11(6):e4962.
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36(1):8-27.
Moore BJ, White S, Washington R, Coenen N, Elixhauser A. Identifying increased risk of readmission and in-hospital mortality using hospital administrative data: the AHRQ Elixhauser Comorbidity Index. Med Care. 2017;55(7):698-705.
Austin PC. Primer on statistical interpretation or methods report card on propensity-score matching in the cardiology literature from 2004 to 2006: a systematic review. Circ Cardiovasc Qual Outcomes. 2008;1(1):62-67.
Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387-398.
Asmarats L, Rodes-Cabau J. Percutaneous left atrial appendage closure: current devices and clinical outcomes. Circulation Cardiovascular interventions. 2017;10(11):e005359.
Healthcare cost and utilization project data use agreement. Accessed December 12, 2020. https://wwwhcup-usahrqgov/DUA/dua_508/DUA508versionjsp#data
Centers for Medicare & Medicaid Services. Accessed on January 1, 2021. https://wwwcmsgov/medicare-coverage-database/details/nca-decision-memoaspx?NCAId=281%26bc=AAAAAAAAQAAA%26%20
Molnar AO, van Walraven C, McArthur E, Fergusson D, Garg AX, Knoll G. Validation of administrative database codes for acute kidney injury in kidney transplant recipients. Can J Kidney Health Dis. 2016;3:18.
Bhat AG, Siddappa Malleshappa SK, Pasupula DK. Recognizing infective endocarditis and drug abuse through ICD codes in administrative databases. J Am Coll Cardiol. 2019;73(22):2907-2908.
Lorence DP, Ibrahim IA. Benchmarking variation in coding accuracy across the United States. J Health Care Finance. 2003;29(4):29-42.

Auteurs

Deepak Kumar Pasupula (DK)

MercyOne North Iowa Medical Center, Mason City, Iowa, USA.
Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.

Muhammad B Munir (MB)

University of California San Diego Health, San Diego, California, USA.

Anusha Ganapati Bhat (AG)

Baystate Medical Center, Springfiled, Massachusetts, USA.

Sudeep K Siddappa Malleshappa (SK)

Baystate Medical Center, Springfiled, Massachusetts, USA.

Srinidhi J Meera (SJ)

Cleveland Clinic, Cleveland, Ohio, USA.

Michael Spooner (M)

MercyOne North Iowa Medical Center, Mason City, Iowa, USA.

Ketan Koranne (K)

MercyOne North Iowa Medical Center, Mason City, Iowa, USA.

Brian Olshansky (B)

University of Iowa, Iowa City, Iowa, USA.

Sameer Hirji (S)

Brigham and Women's Hospital, Boston, Massachusetts, USA.

Jonathan C Hsu (JC)

University of California San Diego Health, San Diego, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH